Akademik Veri Yönetim Sistemi
Journal of RadiationOncology and Research, cilt.2, sa.1, ss.1004-1008, 2018 (Hakemli Dergi)
Radiation therapy is used for adjuvant therapy on patients with recurrence or lymphadenectomy in the malignant melanomas. Treatment is used for palliative on metastatic patients. Between 1996 and 2017, 35 patients who received adjuvant radiotherapy and 55 patients who received palliative radiotherapy were retrospectively analyzed. Of the 90 patients included in the study, 56 (62%) were men and 34 (38%) were women. Mean age of patients was 63 years (age range: 22–95 years). For all patients, the overall survival time was 32.23 months (95% CI, 16.8–47.6). As an adjuvant therapy, 48 Gy (hypofractionated) radiotherapy was used in 4 patients and 50-66 Gy radiotherapy was used in 31 patients. Overall survival in these patients was 66.14 (95% CI 36.6-95.6) months. Mean metastases that occur in patients is 37.19 months (range: 2-138 months), which are 37 (41%) patients in the brain, 12 (13%) patients in the bone and 6 (7%) patients in the non-regional lymph node metastasis. 20-30 Gy radiotherapy was used for metastasis treatment. Overall survival in brain metastasis, bone metastasis and lymph nodes metastatic patients were 4.22 (95% CI 2.62-5.82), 7.6 (95% CI 1.14-14.05) and 7.33 (95% CI 0-15.03) months respectively. Although, the regional nodal disease can be favorably controlled with lymphadenectomy and radiotherapy, the risk of distant metastases and the risk of disease-related death are high. In addition, metastasis-related symptoms (particularly pain) can be controlled by radiotherapy.